Loading organizations...
§ Private Profile · Waltham, MA, USA
Scipher Medicine is a technology company.
Scipher Medicine develops precision immunology solutions for autoimmune diseases, utilizing a proprietary network medicine platform that maps human disease biology. This platform identifies individual patient disease signatures, predicting drug responses to approved therapies and uncovering novel drug targets. Its core technology, Spectra, leverages artificial intelligence to interpret patient molecular data, offering insights into disease mechanisms and patient stratification.
The company was founded in 2013 by Dr. Joseph Loscalzo and Dr. Laszlo Barabasi, building upon their research that began in 2003 into mapping human disease biology. Their foundational insight centered on understanding how proteins expressed from the human genome interact to cause specific disease phenotypes, thereby providing a wiring diagram to interpret dynamic individual patient molecular data. This approach sought to move beyond conventional diagnostic methods by revealing the underlying biological drivers of autoimmune conditions.
Scipher Medicine aims to match each patient with the most effective therapy for their condition, offering solutions that include diagnostics and therapeutics. Their commercial product, PrismRA, is a blood test for patients with rheumatoid arthritis that predicts non-response to anti-TNF therapies, guiding treatment decisions. The company's vision is to personalize treatment for complex diseases by precisely identifying optimal therapies, ultimately improving patient outcomes.
Scipher Medicine has raised $337.0M across 5 funding rounds.
Scipher Medicine has raised $337.0M in total across 5 funding rounds.
Scipher Medicine is a precision immunology company leveraging AI, network biology, and proprietary clinico-genomic data to match patients with effective therapies for autoimmune diseases, primarily rheumatoid arthritis (RA).[1][2][3] Its core product, PrismRA, is a blood-based molecular test that analyzes a patient's unique molecular signature to predict non-response to TNF inhibitor (TNFi) therapies—the world's best-selling drug class—enabling physicians to select alternative treatments and avoid trial-and-error, which affects 20 million RA patients worldwide.[2][4] The company serves rheumatologists, healthcare providers, and pharma partners, solving the problem of ineffective therapies that waste billions annually in healthcare costs and leave patients suffering.[1][4] Scipher also supports drug development and commercialization through its SPECTRA AI platform, which includes vast datasets from over 300K patients, a biobank of molecular samples, and tools for target discovery, therapy selection, and precision analytics.[1][2][3] Growth momentum includes global expansion into Latin America via a partnership with Grupo Amarey in Colombia and collaborations like with Maxymune Therapeutics for target ranking in autoimmune diseases.[2][3]
Scipher Medicine emerged from years of research mapping hundreds of thousands of protein interactions in human cells, building one of the largest molecular data registries and biobanks for non-oncology autoimmune diseases.[1] While specific founders are not detailed in available sources, the company is led by CEO Reg Seeto, who emphasizes eliminating trial-and-error in autoimmune treatments through data-driven insights.[2][3] Early traction centered on developing PrismRA, the first molecular test for RA therapy selection, validated across disease areas and now supported by electronic medical records (EMR) data from over 3 million rheumatology patients.[2][3][4] Pivotal moments include launching SPECTRA platforms for Rx (therapy selection) and Dx (diagnostics), partnerships across healthcare, and recent expansions like the 2024 alliance with Grupo Amarey to bring PrismRA to Latin America.[2]
Scipher rides the precision medicine wave in immunology, where AI and multi-omics data address the "broken" trial-and-error model in autoimmune diseases, a market strained by billions in wasted spending on non-responders.[1][4] Timing is ideal amid rising demand for data-driven drug development—timelines of 10-15 years and $1-3B costs per drug make de-risking tools like SPECTRA essential, predicting failures early and boosting success rates.[5] Favorable forces include explosive growth in clinico-genomic datasets, AI advancements in network biology, and pharma's shift to targeted therapies for 20M+ RA patients globally.[1][2] Scipher influences the ecosystem by partnering across healthcare for biomarker discovery, commercialization analytics, and real-world evidence, accelerating therapies and improving outcomes in underserved regions like Latin America.[2][3]
Scipher is poised to expand PrismRA adoption globally and scale SPECTRA for more autoimmune/inflammatory indications, leveraging its data moat to secure pharma deals and enter new markets.[2][3][5] Trends like AI-driven target de-risking and real-world clinico-genomic integration will propel growth, potentially slashing drug development failures amid rising immunology R&D investments.[3][5] Its influence may evolve into a key enabler for precision therapeutics, transforming patient care from reactive to predictive—ultimately fulfilling its mission to match every patient with optimal therapy.[1]
Scipher Medicine has raised $337.0M across 5 funding rounds. Most recently, it raised $110.0M Other Equity in February 2022.
Scipher Medicine has raised $337.0M in total across 5 funding rounds.
Scipher Medicine's investors include Tim Anderson, Alumni Ventures, Echo Health Ventures, Hitachi Ventures, Khosla Ventures, Laurion Capital Management, Monashee Investment Management, Neuberger Berman, Michael Rubin, Optum Ventures, Cowen Healthcare Investments, aMoon Fund.